|
|
|
By Tom von Gunden, Chief Editor, Drug Delivery Leader | Chief Editor Tom von Gunden comments on the biopharma industry’s interest in leveraging drug delivery platform technologies to reduce regulatory burden. Tom includes his conversation with combination products consultant Doug Mead on the likelihood of regulatory waivers on device-related testing. | |
|
|
Improving Device Usability With Post-Market HF Data | By Alicia Douglas and Zhonghai (John) Li, Merck & Co., Inc. | Post-market Human Factors analyses offer more than a quality metric, they help teams diagnose issues, guide fixes, and improve real-world usability of drug-device products beyond validation. |
|
|
|
| Disposable Pen Delivery For Semaglutide | Infographic | BD Medical - Pharmaceutical Systems | This disposable pen for semaglutide is a generic drug-device combination, designed for usability and regulatory compliance, showing comparable performance to the reference device. |
|
|
| The Future Of Sustained Drug Delivery | Article | Nanoform | Advances in sustained-release drug delivery could improve efficiency and consistency in drug release, manifesting real-life advantages for patients in the form of enhanced accessibility and compliance. |
|
|
|
| Future-Proofing Drug Delivery Production | White Paper | By Otto Abildgaard and Lars Keinicke Hansen, Stevanato Group | Shift from static lines to modular assembly. Combining intelligent software with plug-and-play hardware enables rapid format changes, shortens validation, and unlocks data for scalability. |
|
|
|
|
|
.png){kind=logo}
